Stifel Nicolaus Issues Positive Forecast for Zimmer Biomet (NYSE:ZBH) Stock Price

Key Points

• Zimmer Biomet's price target has been increased to $118.00 by analysts at Stifel Nicolaus, indicating a potential upside of 17.47% from the company's last close.
• The company reported earnings of $2.07 EPS for the quarter, surpassing expectations and showing a revenue increase of 7.0% year-over-year.
• Zimmer Biomet currently has a consensus rating of "Moderate Buy" from analysts, with ten "Buy" ratings and an average target price of $113.16.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its target price raised by analysts at Stifel Nicolaus from $115.00 to $118.00 in a note issued to investors on Friday, MarketBeat.com reports. The firm presently has a "buy" rating on the medical equipment provider's stock. Stifel Nicolaus' price target would suggest a potential upside of 17.96% from the company's previous close.

A number of other research firms also recently issued reports on ZBH. UBS Group increased their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a report on Friday, August 8th. Raymond James Financial increased their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Royal Bank Of Canada increased their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a report on Thursday. They set a "buy" rating and a $130.00 price objective for the company. Finally, Rothschild Redb upgraded Zimmer Biomet to a "strong-buy" rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of "Moderate Buy" and a consensus price target of $113.16.

Zimmer Biomet Stock Down 0.2%

Shares of NYSE ZBH traded down $0.18 during mid-day trading on Friday, reaching $100.03. 4,228,497 shares of the company's stock were exchanged, compared to its average volume of 1,180,396. The firm has a market capitalization of $19.82 billion, a price-to-earnings ratio of 24.34, a PEG ratio of 2.30 and a beta of 0.68. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The business has a fifty day simple moving average of $100.06 and a 200 day simple moving average of $99.39. Zimmer Biomet has a twelve month low of $89.22 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet's revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts expect that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Garde Capital Inc. bought a new position in Zimmer Biomet in the first quarter valued at approximately $29,000. Washington Trust Advisors Inc. bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $30,000. Columbia River Financial Group LLC bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $30,000. Menard Financial Group LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $30,000. Finally, Accent Capital Management LLC bought a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $35,000. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.